https://www.selleckchem.com/GSK-3.html
76, 95% CI [0.51-1.12], p=0.16). Patients undergoing allo-HSCT did better than those receiving TKI plus chemotherapy regarding RFS (HR=0.48, 95% CI [0.37-0.63], p=0.0, and NRS (OR=2.64, 95% CI [1.25-5.57], p=0.0. The NRM rate of the TKI plus chemotherapy group was significantly lower than the allo-HSCT group (OR=2.33, 95% CI [1.51-3.59], p=0.0. TKI combined with chemotherapy can be considered a post-remission treatment option for adult Ph+ ALL patients who are ineligible for allo-HSCT. However, more prospective studies with large sample size
Like
Comment
Share
